Yichao Han
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Yichao Han as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:11 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07890636 · Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLCRuijin Hospital · not yet recruiting · Lung Neoplasm Malignant · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:11 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed
- Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC.J Thorac Oncol · 2021220 citationsRCR 9.6
- 143 citationsRCR 16.0
- 114 citationsRCR 23.0
- Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery.Cytotherapy · 200993 citationsRCR 2.0
- FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.Clin Cancer Res · 202382 citationsRCR 6.7
- CT-guided percutaneous microwave ablation of pulmonary malignancies: Results in 69 cases.World J Surg Oncol · 201268 citationsRCR 2.7
- Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study.Eur J Cancer · 202065 citationsRCR 2.2
- MiR-4782-3p inhibited non-small cell lung cancer growth via USP14.Cell Physiol Biochem · 201464 citationsRCR 1.9
- 41 citationsRCR 1.3
- 34 citationsRCR 1.8